The insufflation devices market is projected to register a CAGR of 6.3% during the forecast period (2022-2027).
The COVID-19 epidemic and the resulting restrictions have altered how healthcare systems operate worldwide. The continuing "coronavirus disease 19" (COVID-19) pandemic has had a significant impact on surgical care delivery around the world. Elective operations have been postponed to devote more resources to COVID-19 patients. According to a research article published in July 2021 titled "Impact of the COVID-19 Pandemic on the Patient's Decision about Bariatric Surgery: Results of a National Survey," bariatric operations were withdrawn in most countries after the International Federation for the Surgery of Obesity, and Metabolic Disorders issued recommendations (IFSO). Approximately 60,000 bariatric procedures per month may have been postponed globally. After a few months, several governments have begun to ease restrictions, such as reopening businesses and public areas, permitting social interaction, and allowing elective surgery to resume. As a result, COVID-19 significantly impacted the market for insufflation devices at the start of the pandemic.
Due to technological developments in surgery, an increase in the number of surgical cases, and an increase in the frequency of uterine fibroids, obesity, and cardiac diseases around the world, the need for insufflation devices is rising. One of the major factors driving market expansion is the rising incidence of obesity due to a sedentary lifestyle and an increase in the consumption of energy-dense meals high in fat and sugar. According to the Trust for America's Health, the adult obesity rate in the United States reached 42.4 percent in 2020, marking the first time the national percentage exceeded 40%.
As insufflation devices are used in bariatric surgery, the rising prevalence of obese persons with a BMI of 35-39 who have certain major health concerns, such as type 2 diabetes, sleep apnea, and high blood pressure, is a high-impact driver of the market. The number of bariatric procedures performed grew from 158,000 in 2011 to 256,000 in 2019, according to the American Society for Metabolic and Bariatric Surgery (ASMBS). Furthermore, as the public becomes more aware of the benefits of bariatric surgery, the demand for insufflation devices as a treatment option has grown.
The laparoscopic surgery segment is projected to grow significantly over the forecast period. Insufflation devices are predicted to rise as the number of laparoscopic procedures conducted worldwide increases due to their benefits. Every year, about 13 million laparoscopic surgeries are performed worldwide, according to the Cleveland Clinic 2022. Over the next five years, these figures are expected to rise by 1%. Laparoscopic surgery is widely used in high-risk patients, such as the elderly, obese patients, and those with preexisting illnesses such as cardiovascular and pulmonary problems. According to the Center for Disease Control and Prevention (CDC) 2020, over 600,000 hysterectomies are performed in the United States each year, and approximately 20 million women in the United States have undergone a hysterectomy. Insufflation devices are projected to be in more demand due to such occurrences.
The segment is being driven by an increase in the use of laparoscopic surgical methods such as laparoscopic cholecystectomy, hernia repair, laparoscopic splenectomy, and hepatectomy worldwide. A few advantages of laparoscopic surgery are a few advantages of reduced postoperative pain, superior cosmetic results, increased patient satisfaction, and a shorter hospital stay. There has also been an increase in the number of laparoscopic emergency operations. Because insufflation devices are commonly employed in laparoscopic procedures, such factors are projected to propel the market forward, thereby boosting the market growth.
Obesity has quickly become a major public health concern. Obesity's economic impact grows in lockstep with its prevalence, owing to both direct and indirect expenditures. The COVID-19 pandemic has negatively influenced obesity, lowering access to bariatric care and treatment of obesity-related disorders while also generating an increasingly obesogenic atmosphere.
North America's market is rising due to its developed healthcare infrastructure, growing demand for innovative technical solutions, and the considerable presence of leading industry participants. In addition, the region's growing desire for less invasive surgeries is expected to enhance the market growth. Access is necessary to allow tools to be inserted into the abdomen during a minimally invasive surgical procedure in the abdomen, such as gallbladder removal.
Technological advances are also helping to drive the market in North America forward. For example, Stryker's 45L PneumoSure XL insufflator offers remarkable performance and improved safety and reliability. Bariatrics and Vessel Harvesting are two additional modes included. This insufflator also includes real-time pressure sensing for improved precision during procedures, but this feature requires special insufflation tubing. The ability of the PneumoSure to maintain pneumoperitoneum under the most extreme situations, along with a fully integrated color touch screen, makes it easier to use in any operating room worldwide. Northgate Technologies, Inc. (NTI) also announced in October 2019 that Vizient, Inc., the biggest member-driven healthcare performance improvement organization in the country, was awarded their NEBULAE I System, High-flow Laparoscopic Insufflator, an Innovative Technology contract. The contract was awarded a NEBULAE I System recommendation from hospital professionals in this field who serve on one of Vizient's member-led councils. Hence, all the abovementioned factors are projected to boost the market’s growth.
The insufflation device market is fragmented and competitive and consists of several major players. Some players operating in the market are STERIS, COMEG, Stryker, B. Braun Medical Ltd, CONMED Corporation, Karl Storz, Olympus, Koninklijke Philips N.V., Bracco Diagnostics Inc., Meditech Systems Ltd, Medtronic, FUJIFILM Holdings America Corporation, Smith & Nephew, and Richard Wolf.
This product will be delivered within 2 business days.
The COVID-19 epidemic and the resulting restrictions have altered how healthcare systems operate worldwide. The continuing "coronavirus disease 19" (COVID-19) pandemic has had a significant impact on surgical care delivery around the world. Elective operations have been postponed to devote more resources to COVID-19 patients. According to a research article published in July 2021 titled "Impact of the COVID-19 Pandemic on the Patient's Decision about Bariatric Surgery: Results of a National Survey," bariatric operations were withdrawn in most countries after the International Federation for the Surgery of Obesity, and Metabolic Disorders issued recommendations (IFSO). Approximately 60,000 bariatric procedures per month may have been postponed globally. After a few months, several governments have begun to ease restrictions, such as reopening businesses and public areas, permitting social interaction, and allowing elective surgery to resume. As a result, COVID-19 significantly impacted the market for insufflation devices at the start of the pandemic.
Due to technological developments in surgery, an increase in the number of surgical cases, and an increase in the frequency of uterine fibroids, obesity, and cardiac diseases around the world, the need for insufflation devices is rising. One of the major factors driving market expansion is the rising incidence of obesity due to a sedentary lifestyle and an increase in the consumption of energy-dense meals high in fat and sugar. According to the Trust for America's Health, the adult obesity rate in the United States reached 42.4 percent in 2020, marking the first time the national percentage exceeded 40%.
As insufflation devices are used in bariatric surgery, the rising prevalence of obese persons with a BMI of 35-39 who have certain major health concerns, such as type 2 diabetes, sleep apnea, and high blood pressure, is a high-impact driver of the market. The number of bariatric procedures performed grew from 158,000 in 2011 to 256,000 in 2019, according to the American Society for Metabolic and Bariatric Surgery (ASMBS). Furthermore, as the public becomes more aware of the benefits of bariatric surgery, the demand for insufflation devices as a treatment option has grown.
Key Market Trends
The Laparoscopic Surgery Segment is Expected to Hold a Major Market Share in the Insufflation Devices Market
The laparoscopic surgery segment is projected to grow significantly over the forecast period. Insufflation devices are predicted to rise as the number of laparoscopic procedures conducted worldwide increases due to their benefits. Every year, about 13 million laparoscopic surgeries are performed worldwide, according to the Cleveland Clinic 2022. Over the next five years, these figures are expected to rise by 1%. Laparoscopic surgery is widely used in high-risk patients, such as the elderly, obese patients, and those with preexisting illnesses such as cardiovascular and pulmonary problems. According to the Center for Disease Control and Prevention (CDC) 2020, over 600,000 hysterectomies are performed in the United States each year, and approximately 20 million women in the United States have undergone a hysterectomy. Insufflation devices are projected to be in more demand due to such occurrences.
The segment is being driven by an increase in the use of laparoscopic surgical methods such as laparoscopic cholecystectomy, hernia repair, laparoscopic splenectomy, and hepatectomy worldwide. A few advantages of laparoscopic surgery are a few advantages of reduced postoperative pain, superior cosmetic results, increased patient satisfaction, and a shorter hospital stay. There has also been an increase in the number of laparoscopic emergency operations. Because insufflation devices are commonly employed in laparoscopic procedures, such factors are projected to propel the market forward, thereby boosting the market growth.
North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.
Obesity has quickly become a major public health concern. Obesity's economic impact grows in lockstep with its prevalence, owing to both direct and indirect expenditures. The COVID-19 pandemic has negatively influenced obesity, lowering access to bariatric care and treatment of obesity-related disorders while also generating an increasingly obesogenic atmosphere.
North America's market is rising due to its developed healthcare infrastructure, growing demand for innovative technical solutions, and the considerable presence of leading industry participants. In addition, the region's growing desire for less invasive surgeries is expected to enhance the market growth. Access is necessary to allow tools to be inserted into the abdomen during a minimally invasive surgical procedure in the abdomen, such as gallbladder removal.
Technological advances are also helping to drive the market in North America forward. For example, Stryker's 45L PneumoSure XL insufflator offers remarkable performance and improved safety and reliability. Bariatrics and Vessel Harvesting are two additional modes included. This insufflator also includes real-time pressure sensing for improved precision during procedures, but this feature requires special insufflation tubing. The ability of the PneumoSure to maintain pneumoperitoneum under the most extreme situations, along with a fully integrated color touch screen, makes it easier to use in any operating room worldwide. Northgate Technologies, Inc. (NTI) also announced in October 2019 that Vizient, Inc., the biggest member-driven healthcare performance improvement organization in the country, was awarded their NEBULAE I System, High-flow Laparoscopic Insufflator, an Innovative Technology contract. The contract was awarded a NEBULAE I System recommendation from hospital professionals in this field who serve on one of Vizient's member-led councils. Hence, all the abovementioned factors are projected to boost the market’s growth.
Competitive Landscape
The insufflation device market is fragmented and competitive and consists of several major players. Some players operating in the market are STERIS, COMEG, Stryker, B. Braun Medical Ltd, CONMED Corporation, Karl Storz, Olympus, Koninklijke Philips N.V., Bracco Diagnostics Inc., Meditech Systems Ltd, Medtronic, FUJIFILM Holdings America Corporation, Smith & Nephew, and Richard Wolf.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- STERIS
- COMEG
- Stryker
- B. Braun Medical Ltd
- CONMED Corporation
- Karl Storz
- Olympus
- Koninklijke Philips N.V.
- Bracco Diagnostics Inc.
- Baptist Health
- Medtronic
- FUJIFILM Holdings America Corporation
- Smith & Nephew
- Richard Wolf
Methodology
LOADING...